Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise by Stephens, R J et al.
It is surprising that although many cancer treatment trials are
palliative in intent, there is no agreed definition of ￿palliation￿ or a
standard approach to its measurement. Yet, if palliative treatments,
whether they be for symptoms of the disease or side-effects of the
cancer treatment, are to be compared, some precision in the assess-
ment of treatment policies is essential. It is our concern that the
reporting of symptom palliation is often oversimplified, and that in
fact it is deceptively difficult to uncover the real effect of treatment
on patient groups.
With the introduction of health-related quality of life (QL) ques-
tionnaires to measure longitudinal changes in a broad range of
symptoms, it was expected that a more detailed evaluation of palli-
ation would be feasible. The Medical Research Council (MRC)
Lung Cancer Working Party (LCWP) has used such an instrument,
the Rotterdam Symptom Checklist (RSCL) (De Haes et al, 1990),
in successive trials. It has become apparent that the analyses of
these data pose some formidable problems, partly because of high
attrition rates and missing data (Hopwood et al, 1994) and partly
because of the lack of an agreed definition of palliation. Indeed,
the definition of the word ￿palliation￿ and the level of complexity
with which it is reported vary enormously.
THE STATE OF THE ART: A REVIEW OF THE
LITERATURE
In published reports, ￿palliative treatment￿ may simply reflect non-
curative treatment, with no information provided on relief of
presenting symptoms [e.g. trials of palliative chemotherapy in
small-cell lung cancer (James et al, 1996) and hormonal palliation
of ovarian cancer (Ahlgren et al, 1993)]. In other reported trials,
palliation is defined as the treatment given to prevent medical
conditions arising [e.g. pamidronate to prevent hypercalcaemia
and bone pain in patients with bone metastases (van Holten-
Verzantvoort et al, 1993)].
When relief of symptoms is considered, the most straight-
forward analyses are those in which the primary end point is the
resolution of a specific symptom [e.g. sucralfate to palliate acute
radiation oesophagitis (Sur et al, 1994) or granisetron as an
antiemetic in cytostatic-induced emesis (Marty et al, 1992)].
Occasionally, when treatment affects a number of symptoms, the
individual symptoms are listed and their palliation reported [e.g.
neurological symptoms in patients with brain metastases (Kurtz et
al, 1981) or general symptoms resulting from hepatic metastases
(Mohiuddin et al, 1996)].
When assessments have been made over several symptoms or
time points, authors have used a variety of methods of simplifying
analysis and presentation by summarizing the symptoms or the
time points. For example, Lewington et al (1991) combined
change in general condition, mobility, analgesic use and pain into
a symptom response. In contrast, Barr et al (1990) compared the
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￿mean￿ and ￿best￿ dysphagia score against baseline, and Ball et al
(1997) calculated an average grade for each symptom.
All too often, results presented give scant information on how
symptoms were measured, by whom, when, for how long, and
what the severity was at baseline and thereafter (e.g. Haie-Meder
et al, 1993; Buroker et al, 1994). Nevertheless, a number of groups
have investigated more innovative ways of analysing palliation in
the context of their trials.
Burris and Storniolo (1997) attempted to demonstrate ￿clinical
benefit￿, and categorized their patients as responders based on
changes in pain (analgesia use or intensity), Karnofsky perfor-
mance status and weight. Such an approach is potentially useful,
but requires considerable preparatory work.
Tong et al (1982), investigating radiotherapy schedules to
palliate symptomatic bone metastases, considered the promptness
of pain relief. However, as the authors point out, the comparison
was based not on when relief occurred, but when it was reported,
which introduces the possibility of bias.
Tannock et al (1996), in a trial of chemotherapy for prostate
cancer, devised a palliative response based on pain intensity and
analgesic intake. They then used Kaplan—Meier plots to show the
duration of palliation.
Leibel et al (1987) considered the palliation achieved within
groups of patients who had different levels of initial severity. This
indicated that a greater proportion of patients with moderate or
severe abdominal pain reported relief after treatment than those
with mild pain, but that complete response was less often achieved.
A palliation index in patients with lung cancer (Muers and Round,
1993) was based on the duration of response divided by the duration
of survival. Importantly, this definition included the concept of
symptom control, so that palliation encompassed patients with
initially no symptoms or mild symptoms which did not get worse.
There is little evidence, however, that any of these potentially
useful methods have been repeated by the authors or applied more
widely.
The MRC LCWP have used a variety of methods of examining
clinician-rated symptom relief in a series of trials of palliative
radiotherapy in non-small-cell lung cancer (NSCLC) and pallia-
tive chemotherapy in small-cell lung cancer (SCLC). In three trials
(MRC LCWP, 1991, 1992, 1993), the duration of improvement of
individual presenting symptoms was calculated and then (as with
Muers and Round, 1993) presented as a proportion of survival
time. In addition, the proportion of patients achieving complete
resolution of presenting symptoms and duration of palliation was
reported, and better palliation in patients with initially moderate or
severe symptoms was noted. In two further trials (MRC LCWP,
1996a, b), Kaplan—Meier plots were used to estimate the
frequency of palliation of individual patient-reported symptoms by
specified time points. Finally, in the most recently published trial
(MRC LCWP, 1996c), a palliation score was devised to incorpo-
rate four key symptoms, and changes in this score from baseline to
3 months, importantly including patients who died before 3
months as non-palliated, were compared.
AIM
The aim of this paper is to report exploratory analyses that high-
light some of the advantages and disadvantages of published
methods, and to try to develop a generally applicable definition of
symptom palliation in clinical trials. To do this, we have used data
from patient-completed RSCL questionnaires in an MRC LCWP
trial because this is typical of the data available in many trials.
However, the concepts are relevant to any assessments of symp-
toms, whether they be by the patient or the clinician or on any
standard QL questionnaire.
DATA USED
Data from the MRC LCWP LU12 trial (MRC LCWP, 1996b) was
used in this analysis. In the LU12 trial, patients with extensive
disease SCLC, or limited disease but poor performance status
[WHO grade 3 or 4 (WHO, 1979)], were allocated at random to
receive three 3-weekly cycles of either a four-drug regimen —
etoposide, cyclophosphamide, methotrexate and vincristine (4D) or
a two-drug regimen — etoposide and vincristine (2D) as palliative
treatment. The 4D regimen had been shown in previous MRC trials
(MRC LCWP, 1989a, b) to be an effective treatment for SCLC, and
the aim of this trial was to see if, in poor prognosis patients, the 2D
regimen would prove equally effective but less toxic.
A total of 310 patients (154, 4D; 156, 2D) were randomized from
23 centres in the UK. There was no difference in survival between
the two treatment groups (medians: 4D, 141 days; 2D, 137 days),
and levels of palliation were reported to be similar, but patients on
the 4D regimen had more haematological toxicity and more early,
possibly treatment-related, deaths (Stephens et al, 1994).
Assessment of Quality of Life
QL was assessed by patients using the RSCL, a patient-completed
categorical scale consisting of 38 core items to which four lung
cancer-specific symptoms (chest pain, cough, hoarseness and
Table 1 Patient sample for analysis
4D regimen 2D regimen Total
(n)( n)( n)
Total patients 154 156 310
No baseline data 16 29
Baseline completed too late (> 7 days) 1 1
No follow-up RSCLs completed 49 23
No cough at baseline 17 17
Remaining for analysis 71 86 157 (51%)
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Figure 1 Kaplan–Meier plot of duration of symptom improvement540 RJ Stephens et al
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coughing up blood) were added. Patients were asked to tick boxes
to indicate how they had been feeling during the past week. In this
paper, these categories are referred to as nil, mild, moderate and
severe. Questionnaires were completed pretreatment, at each atten-
dance for protocol chemotherapy, then monthly to 6 months from
randomization, 2 monthly to 1 year, and 3 monthly thereafter.
Analyses
For the sake of simplicity, we have focused on one major disease-
related symptom (cough).
Compliance was assessed according to the method proposed by
Hopwood et al (1994), which gave an overall compliance of 56% in
the first 6 months falling from 85% at baseline to 31% at 6 months.
Such low levels of compliance, which are not unusual in palliative
trials, affect the analysis of palliation. For example, to compare the
treatments in terms of improving the severity of cough by one grade
or more at any follow-up from baseline, Table 1 shows that, of the
154 4D and 156 2D patients randomized, 16 and 29, respectively,
did not complete a baseline RSCL; a further one and one completed
the form outside the specified time window; 49 and 23 completed
no follow-up questionnaires; and 17 and 17 patients did not report
having a cough at baseline. There thus remain 71 4D and 86 2D
patients for any comparison of improvement of cough.
Aspects of palliation
By synthesizing some of the ideas in the published papers, we
propose that palliation can be viewed as a three-dimensional
concept, namely, time of onset, duration and degree.
Onset of symptom improvement
Considering the 157 patients with data available for analysis
(Table 1), the majority of patients reported an almost immediate
improvement, but 12 (11% of the patients who reported improve-
ment) reported this later than 2 months from starting treatment. In
one of these 12 patients, this was simply due to the absence of any
earlier assessments, but the remaining 11 patients had intermediate
assessments at which they reported no change or indeed a
worsening cough.
When assessing time to onset of palliation, the timings and
frequency of questionnaire administration and patient compliance
are vitally important, and the time period over which palliation is
to be assessed should be limited to that period when trial regimens,
rather than additional interventions, will be influencing events.
One possible method of treatment comparison of the time of
onset of symptom relief uses Kaplan—Meier plots: the time that
improvement was first reported is taken as the event, with patients
not reporting improvement being censored at the date of their last
QL questionnaire completion (MRC LCWP, 1996a, b). The main
advantage of this method is that all patients reporting cough at
baseline can be included. The major disadvantage is that it
assumes that censored patients [those not achieving the event
(palliation) whether they be alive or dead] are assumed to follow
the same pattern as those who do. Thus, a treatment with poor
survival but good palliation among the survivors can appear better
than a treatment with good survival and variable palliation, even if
the actual number of patients alive and with palliation is exactly
the same in both treatments. Similarly, any unequal reduction in
group sample sizes must be considered worrying, e.g. Buroker et al
(1994), from initial group samples of 183 and 179, compared 122
with 90 in terms of palliation.
If time to onset is too difficult a concept to include in an overall
definition of palliation, at least limiting the period over which
palliation is assessed ensures that it is related to the treatment
being studied.
Duration of improvement
Kaplan—Meier plots can be used to estimate and compare the
proportion of patients who remain alive and with symptom improve-
ment because it is reasonable to assume that patients censored will
die or relapse at the same rate as their contemporaries. Figure 1 is
based on 56 4D and 52 2D patients who reported improvement in
cough. There was no statistically significant difference between the
regimens (P = 0.32) using this method of comparison.
Of course, the accuracy of these figures relates to the frequency
of assessment. The dates of symptom improvement and deteriora-
tion have to be taken as the date of the assessment at which the
event was first reported, which could be weeks or even months
after the previous assessment and after the actual event.
Table 2 Improvement according to initial severity of cough
Initial severity Total Not improved Improved to Total (%)
of cough Regimen patients no. (%)
Nil Mild Moderate
Severe 4D 16 0 (0) 8 4 4 16 (100)
2D 18 3 (17) 8 7 0 15 (83)
Moderate 4D 19 1 (5) 8 10 – 18 (95)
2D 15 3 (20) 9 3 – 12 (80)
Mild 4D 36 14 (39) 22 – – 22 (61)
2D 53 28 (53) 25 – – 25 (47)
Table 3 Improvement in severity of cough at different time points
Time from Patients Improvement
randomization Regimen assessed no. (%) P-value
1 month 4D 64 40 (62)
2D 76 31 (41) 0.02
2 months 4D 36 18 (50)
2D 50 30 (60) 0.50
3 months 4D 25 16 (64)
2D 32 12 (38) 0.09Defining and analysing symptom palliation 541
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One simple way of incorporating duration into any definition of
palliation is to ensure that the palliation reported is sustained, not
transient or due to day-to-day changes. Thus, as with the WHO
definition of tumour response (WHO, 1979) and as used by
Tannock et al (1996), improvement should only be accepted if it is
reported on two successive assessments at least 3 weeks apart.
Degree
The degree of symptom relief was analysed according to the
severity at presentation. Improvement in severity of cough was
related to the reported baseline severity (as shown in Table 2).
Thus, in the 4D group, of the patients who reported severe cough
at baseline, all 16 (100%) reported improvement, compared with
18 (95%) of those who reported moderate cough at baseline and
only 22 (61%) who reported a mild cough. The corresponding
figures for the 2D group were 83%, 80% and 47%.
Therefore, different criteria for ￿palliation￿ are required for
patients presenting with different symptom severity. These can be
referred to as improvement, control and prevention.
Improvement
The intuitive definition of palliation is that the symptom is
relieved. Given the wide use of a four-point categorical severity
scale, this is inevitably defined as an improvement in symptom
rating by one or more categories (Sur et al, 1994; MRC LCWP,
1991, 1992, 1993, 1996a—c). Inevitably, patients without the
symptom at presentation are excluded.
Control
As suggested by Muers and Round (1993), for those patients with
absent or mild symptoms at presentation it makes clinical sense to
consider control, i.e. the symptom does not develop or, if mild, get
worse.
Prevention
Another way of including the patients reporting no initial symp-
toms is to include prevention as part of palliation (e.g. van Holten-
Verzantvoort et al, 1993).
Thus, all patients can be encompassed in a definition which
requires improvement in those with initially moderate or severe
symptom, improvement or control for those with mild symptom, and
prevention in those with no symptom. This accords with the defini-
tion of palliation outcome measures described by Maher et al (1994).
SELECTING THE TIME POINT FOR ANALYSIS
The landmark analysis, calculating the change from baseline to a
specific time point, is most often used in the analysis of palliation.
However, there are two distinct methods, both with inherent prob-
lems. Using all the available data results in a diminishing sample
[e.g. Twelves et al (1994) compared 14 patients at baseline with 12
at 6 weeks], which is not strictly comparable and does not account
for the fact that any improvement seen may simply be due to
patients who are more ill dropping out. Alternatively, using only
those patients with data at both time points does not allow for the
fact that such patients, who must be survivors and compliers, may
not be representative of the whole sample, e.g. Brewster et al
(1995) could use only 161 patients with data at baseline and at 6
weeks out of their sample of 197, and Richards et al (1992) could
use only 42 out of 53 patients at pre- and post-treatment.
Our paper discussing this problem (Hopwood et al, 1994)
suggests that, in order to utilize all the data, it is first necessary to
show that the scores from patients completing different numbers
of questionnaires (for whatever reason) are similar. Glimelius et al
(1996) produced charts to show similar patterns of symptom
severity in subgroups of patients within each regimen, and more
importantly differences between regimens. However, as there are
no simple statistical methods to compare plots composed of dimin-
ishing populations over time, such comparisons can only be
descriptive. Thus, using only those patients with data at both base-
line and the landmark time point is the preferred option.
In Table 3, three time points were considered: 1, 2 and 3 months
from randomization. For each, the denominator was the number of
patients with a reported cough at baseline and follow-up data at
that specific time point, and the proportion of patients is reported
whose grade of cough improved compared with baseline.
Table 4 Analysis of palliation of cough, based on different definitions of palliation
Early deaths included
in the denominator
Patients palliated/ Patients palliated/
Definition of palliation Regimen assessed (%) P-value assessed (%) P-value
(i) Improvement at one or 4D 56/71 (79) 56/92 (61)
more assessments 2D 52/86 (60) 0.02 52/97 (54) 0.39
(ii) Disappearance at one or 4D 38/71 (54) 38/92 (41)
more assessments 2D 42/86 (49) 0.67 42/97 (43) 0.90
(iii) Improvement at two 4D 33/58 (57) 33/82 (40)
successive assessments 2D 27/65 (42) 0.13 27/78 (35) 0.58
(iv) Improvement of moderate 4D 30/35 (86) 30/47 (64)
or severe to mild or nil at 2D 27/33 (82) 0.92 27/37 (73) 0.51
one or more assessments
(v) Improvement of moderate or
severe to mild or nil at one
or more assessments, 4D 62/88 (70) 62/121 (51)
and mild or nil remaining 2D 66/103 (64) 0.44 66/115 (57) 0.41
at mild or nil at all assessments542 RJ Stephens et al
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At 1 month and at 3 months, the 4D regimen emerged superior
(and at 1 month significantly so, P = 0.02), whereas at 2 months
the 2D regimen appeared favourable. The selection of time point
appears critical, and it is very concerning to find that conflicting
results can be obtained.
Considering several time points results in multiple comparisons
and the need to adjust the level of statistical significance, there-
fore, reporting improvement at any one assessment over a speci-
fied period of time is probably more reliable than choosing one
landmark time point.
ANALYSIS OF PALLIATION: EXAMPLES OF
METHODS IN USE
Five different definitions of palliation, each of which is commonly
reported or presented, were applied to the MRC data set, and the
proportions of patients reporting palliation of cough compared.
The results are summarized in Table 4. In addition, to avoid the
possibility that differences in survival biased results, for each
analysis we added a subsidiary analysis in which the patients
excluded because of early death were included as non-palliated
(MRC LCWP, 1996c).
(i) Improvement from baseline by one or more categories at
any subsequent assessment.
This is the most commonly used definition (MRC LCWP,
1991, 1992, 1993).
The population for this analysis are the 157 patients who
reported having a cough at baseline and had at least 1
follow-up assessment (see Table 1). If the score for cough
on any of the follow-up assessments is lower than that
reported at baseline, that patient is considered to have been
palliated. The analysis suggests a benefit for the 4D group
(4D, 79%; 2D, 60%; P = 0.02).
However, if the patients who reported having a cough at
baseline, but who died before completing the first follow-up
QL questionnaire are added to the denominator, then this
difference disappears: 4D, 61%; 2D, 54%; P = 0.39.
(ii) Disappearance of symptom at any subsequent assessment
In some circumstances, the aim of treatment is to
eradicate symptoms completely. Using the same 157
patients as in definition (i), in this case only those who
reported ￿nil￿ at any subsequent assessment were considered
palliated. The 4D regimen again emerged as superior to 2D
(4D, 54%; 2D, 49%), but not statistically significantly so.
Adding in the patients who reported cough at baseline,
but who died, to the denominator changed the apparent
outcome, with the 2D regimen now achieving 43%
palliation and the 4D achieving 41%.
(iii) Improvement from baseline by one or more categories at
two successive assessments.
In an attempt to ensure that palliation obtained is
clinically beneficial and not merely transient, palliation may
be defined as symptom improvement sustained over two
successive follow-up assessments (Tannock et al, 1996). In
our data, the study population was reduced from the 157
used in definitions (i) and (ii) to 123 (58, 4D; 65, 2D), as 34
patients (13 and 21 respectively) only had one follow-up QL
questionnaire assessment and were excluded. The benefit
appeared to be associated with the 4D regimen: 4D, 57%
palliated; 2D, 42%; P = 0.13.
In addition to the 21 and 11 patients, respectively, who
reported a cough at baseline but who died before the first
follow-up assessment and, therefore, can be classed as ￿not
palliated￿, we can also include three and two patients,
respectively, who reported a cough at baseline, completed a
QL questionnaire at first follow-up, but died before the
Table 5 Proposed definition of palliation (based on two successive assessments in the first 3 months)
4D regimen (n) 2D regimen (n)
Total patients 154 156
Excluded from the analysis
No baseline data 16 29
Baseline completed >7 days
after randomization 1 1
Patients with inadequate
follow-up data 33 37
Remaining for the analysis 104 89
Palliated/assessed (%) Palliated/assessed (%)
Improvement
(from moderate 16/26 (62) 12/22 (55)
or severe to mild or nil)
Control
(mild, not getting worse) 24/29 (83) 29/40 (72)
Prevention
(nil, not getting worse) 5/12 (42) 8/13 (62)
Subtotal 45/67 (67) 49/75 (65) P = 0.96
Died without palliation 37 14
Total 45/104 (43) 49/89 (55) P = 0.14Defining and analysing symptom palliation 543
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second follow-up. Adding these patients into the
denominator gives palliation rates of 40% and 35% for the
4D and 2D patients respectively, P = 0.58.
(iv) Improvement from baseline of moderate or severe to mild or
nil at any assessment.
There may be situations in which the aim of palliative
treatment is to concentrate on patients with more severe
symptoms. In this definition, only those with moderate or
severe cough at presentation are considered, and only those
who report this reduced to mild or nil are ￿palliated￿. In our
dataset, the initial sample size was thus reduced from 157
patients to 68. The level of palliation achieved with this
definition appeared higher than with previous definitions
(4D, 86%; 2D, 82%) because, as already shown, of
improvement being easier to demonstrate in patients with
moderate or severe symptoms. This analysis suggests that
there is no significant difference between the regimens.
Using this definition, we can add in the 16 patients (12,
4D; 4, 2D) who reported a moderate or severe cough at
baseline and who died before the first follow-up assessment.
This, as with definition (ii), suggests a non-significant
benefit from the 2D regimen (4D, 64%; 2D, 73%).
(v) Improvement from baseline of moderate or severe to mild or
nil, or no deterioration in mild or nil.
Other groups have suggested that the aim of palliation is
not merely to relieve, but to control and to prevent
symptoms. One major benefit of this definition is that it
allows the inclusion of 34 patients (see Table 1), who
reported no cough at baseline assessment but completed at
least one follow-up questionnaire. Thus, those patients
whose cough was moderate or severe at baseline must
improve to nil or mild at some point (definition iv), and
those with nil or mild at baseline must not get worse at any
subsequent assessment. The analysis shows a non-significant
benefit from the 4D regimen (4D, 70%; 2D, 64%).
In addition to the 32 patients (21, 4D; 11, 2D) who
reported a cough at baseline but died before their first
follow-up, we can also include the 13 (12, 4D; 1, 2D) who
reported no cough at baseline, but who died. This suggests a
slight benefit from the 2D regimen (4D, 51%; 2D, 57%).
Summary
It is reassuring that, if the early deaths are not included as non-
palliated, for all five definitions the same regimen emerged as the
more effective of the two. However, the level of palliation, the size
of the difference and the associated P-values varied widely.
Clinicians￿ opinions of the palliative capacity of regimens, as well
as the importance that they are likely to attach to differences
between regimens, could therefore depend to a considerable extent
on the definition used.
However, when account was taken of early deaths, by scoring
these patients as ￿not palliated￿ the results were inconsistent, and,
although never reaching statistical significance, the benefit tended
to favour the 2D regimen.
APPLICATION OF THE PROPOSED DEFINITION
OF PALLIATION
Because of the observed inconsistencies, we believe it is necessary
to encompass improvement, control, prevention, degree, duration
and onset. The results of this analysis are shown in detail in Table
5. The period of assessment was limited to the first 3 months from
randomization, patients with moderate or severe cough at baseline
were required to show improvement (a reduction to nil or mild on
two successive assessments), those with mild cough at baseline to
show control (not getting worse), and those with no symptoms to
show no deterioration (prevention). To be included in this analysis,
therefore, patients had to have completed questionnaires at base-
line and at two successive follow-up assessments in the first 3
months, and those who died before the second follow-up but with
complete data were included as ￿not palliated￿.
Using these criteria, a total of 117 patients (38%) were
excluded, mainly because of lack of data, leaving 104 4D and 89
2D patients. Of the patients who started with moderate or severe
cough, this improved to no or mild cough in 62% of the 4D
patients and 55% of the 2D patients. Of the patients who started
with a mild cough, this either remained mild or improved to nil in
83% 4D and 72% 2D. Finally, of the patients who started treatment
without a cough, this did not develop in 42% 4D and 62% 2D. In
total, therefore, 67% 4D and 65% 2D were considered to be palli-
ated using this definition.
Adding in as ￿not palliated￿ those patients who died, the balance
shifts towards the 2D regimen, with 43% 4D and 55% 2D
achieving palliation.
CONCLUSION
Symptom palliation is likely to be a major end point in cancer
therapy trials when it is unrealistic to aim for cure, as well as in
other comparisons of treatments aimed at symptom relief or
control (e.g. analgesics, antiemetics). Clinicians would benefit
greatly from being able to compare published trial results and
extract clinically relevant outcomes to discuss treatment decisions
with their patients. Agreeing a definition of palliation in this
context is an essential next step, and one that warrants urgent
consideration given the amount of QL data currently being gener-
ated in palliative treatment trials.
For simplicity in our analyses, we used a single symptom,
cough. In analysing the QL aspects of a clinical trial, it would be
unwise, because of the dangers of multiple comparisons, as well as
unwieldy, to present the results of every individual item.
Nevertheless, we would also argue that combining items into
subscales or domains can sometimes mask important differences
in individual symptoms. The recommended approach is to set out
predefined hypotheses, which also will have the advantage of
helping to choose the correct questionnaire, deciding on the timing
of administration, and of calculating a suitable sample size.
We recognize that our methods are not exhaustive or necessarily
the best, but our aim has been to draw attention to the problems
inherent in assessing palliation, to tease out the advantages and
disadvantages and make some preliminary recommendations.
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